Table 1.

Therapeutic agents that enhance replicative stress.

Target/mechanism	Compounds	Stage of development	Reference
DNA misincorporation/modification	Alkylating agents e.g., cyclophosphamide, temozolamide, etc.	Approved	[20]
	Platinum compounds e.g., cisplatin, carboplatin, etc.	Approved	[21]
Ribonucleotide reductase	Gemcitabine	Approved	[24]
Thymidylate synthetase	5-fluorouracil	Approved	[25]
Topoisomerase I	Irinotecan, topotecan	Approved	[29]
Topoisomerase II	Etoposide, doxrubicin	Approved	[30]
Chk1	UCN-01	Phase I/II. Multiple studies completed	[34,40]
	LY2606368	Phase I/II, one study completed	[36]
	AZD7762	Phase I. One completed.	[41,42]
ATR	AZD6738	Phase I, one study completed	[37]
PARP1	Olaparib and niraparib	Approved	[43,44,45]
WEE1	MK-1775	Phase I	[46,47]
MELK	OTS167	Phase I, 2 studies	[48,49]
NAE	MLN4924	Phase I, multiple studies	[50]